Barrington Research Issues Positive Forecast for LeMaitre Vascular (NASDAQ:LMAT) Stock Price

LeMaitre Vascular (NASDAQ:LMAT) had its target price upped by Barrington Research from $92.00 to $93.00 in a report released on Friday, Benzinga reports. The firm currently has an outperform rating on the medical instruments supplier’s stock. Barrington Research also issued estimates for LeMaitre Vascular’s Q4 2024 earnings at $0.49 EPS, FY2024 earnings at $1.94 EPS, Q1 2025 earnings at $0.54 EPS, Q3 2025 earnings at $0.55 EPS and FY2025 earnings at $2.28 EPS.

A number of other brokerages also recently issued reports on LMAT. Cantor Fitzgerald initiated coverage on LeMaitre Vascular in a report on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price target on the stock. JMP Securities increased their price target on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 20th. Lake Street Capital assumed coverage on LeMaitre Vascular in a research report on Friday, August 2nd. They set a “buy” rating and a $105.00 price target on the stock. Finally, StockNews.com downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Tuesday, August 27th. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $94.57.

LeMaitre Vascular Trading Up 1.5 %

NASDAQ LMAT opened at $96.35 on Friday. LeMaitre Vascular has a 12 month low of $47.72 and a 12 month high of $101.67. The stock has a market cap of $2.16 billion, a price-to-earnings ratio of 52.65, a PEG ratio of 2.38 and a beta of 0.89. The company’s 50 day moving average is $89.70 and its two-hundred day moving average is $83.49.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business had revenue of $54.82 million for the quarter, compared to the consensus estimate of $53.50 million. During the same period in the prior year, the business posted $0.33 earnings per share. The company’s quarterly revenue was up 15.6% compared to the same quarter last year. Sell-side analysts forecast that LeMaitre Vascular will post 1.94 EPS for the current year.

LeMaitre Vascular Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 5th. Investors of record on Thursday, November 21st will be paid a $0.16 dividend. This represents a $0.64 annualized dividend and a yield of 0.66%. The ex-dividend date of this dividend is Thursday, November 21st. LeMaitre Vascular’s dividend payout ratio is currently 34.97%.

Insiders Place Their Bets

In related news, Director David B. Roberts sold 3,063 shares of the stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total value of $251,380.41. Following the completion of the transaction, the director now directly owns 14,114 shares in the company, valued at approximately $1,158,335.98. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 10.79% of the company’s stock.

Institutional Investors Weigh In On LeMaitre Vascular

A number of hedge funds have recently added to or reduced their stakes in LMAT. Conestoga Capital Advisors LLC raised its stake in LeMaitre Vascular by 1.9% in the third quarter. Conestoga Capital Advisors LLC now owns 1,978,351 shares of the medical instruments supplier’s stock valued at $183,769,000 after buying an additional 36,850 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of LeMaitre Vascular by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 1,553,834 shares of the medical instruments supplier’s stock valued at $103,112,000 after buying an additional 4,964 shares during the period. Copeland Capital Management LLC grew its holdings in LeMaitre Vascular by 1.0% during the third quarter. Copeland Capital Management LLC now owns 1,163,392 shares of the medical instruments supplier’s stock worth $108,068,000 after acquiring an additional 11,318 shares during the period. Congress Asset Management Co. boosted its position in shares of LeMaitre Vascular by 2.6% during the 3rd quarter. Congress Asset Management Co. now owns 709,316 shares of the medical instruments supplier’s stock worth $65,888,000 after purchasing an additional 18,295 shares in the last quarter. Finally, Driehaus Capital Management LLC grew its stake in shares of LeMaitre Vascular by 52.2% during the 2nd quarter. Driehaus Capital Management LLC now owns 264,217 shares of the medical instruments supplier’s stock worth $21,740,000 after purchasing an additional 90,573 shares during the period. 84.64% of the stock is currently owned by institutional investors and hedge funds.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.